MedTrace Logo

Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors

NCT04450901 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2022-12-05

No results posted yet for this study

Summary

This is a Phase 1/2a, open-label, multicenter, dose-escalation/dose-expansion study of YBL-006, in participants with Advanced Solid Tumors. This multicenter study will be conducted in approximately 11-14 participants in the dose escalation phase, and approximately 39-76 participants in dose expansion phase.

Conditions

Interventions

DRUG

YBL-006

Route of Administration: IV infusion; 0.5 mg/kg Q2W

DRUG

YBL-006

Route of Administration: IV infusion; 2 mg/kg Q2W

DRUG

YBL-006

Route of Administration: IV infusion; 5 mg/kg Q2W

DRUG

YBL-006

Route of Administration: IV infusion; 10 mg/kg Q2W

DRUG

YBL-006

Route of administration : IV infusion, 200 mg Q2W

DRUG

YBL-006

Route of administration : IV infusion, 300 mg Q3W

DRUG

YBL-006

Route of administration : IV infusion, 300 mg Q2W

DRUG

YBL-006

Route of administration : IV infusion, 200mg Q2W

Sponsors & Collaborators

  • Novotech (Australia) Pty Limited

    collaborator INDUSTRY

  • Y Biologics Inc.

    lead INDUSTRY

Principal Investigators

  • Yoon Jaebong · Y-Biologics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2023-03-31
Completion
2023-03-31

Countries

  • Australia
  • South Korea
  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04450901 on ClinicalTrials.gov